Remove Contamination Remove Contract Manufacturing Remove Pharma Companies Remove Production
article thumbnail

CMO Moves: Regulatory catalysts for drug manufacturing-April

Pharmaceutical Technology

Pharmaceutical Technology looks at drugs and biologics with recent regulatory verdicts that will likely impact manufacturing volumes. In this ongoing series , we put a spotlight on contracts between pharma companies and contract manufacturing organizations (CMOs). Covid-19 vaccines stay in the spotlight.

article thumbnail

The rising importance of containment in small molecule drug development

Pharmaceutical Technology

Manufacturing these highly potent and often cytotoxic drugs introduces many risks for operators and the environment. Cross-contamination of standard products with highly potent ones is another key concern. Many companies are now prioritising investments in containment systems, GlobalData research shows.

article thumbnail

A winning combination: The benefits of micronization and containment in a single installation

Pharmaceutical Technology

This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Additionally, over-heating of the product can affect its efficacy or shelf life and bring an increased threat of explosion.